Abstract | BACKGROUND: A Cochrane Collaboration review (Roderick, Cochrane Data base of systemic reviews 2007, DOI 10.1002/14651858.CD0018.90.pub3) reported that there was no evidence for correction of acidosis by sodium bicarbonate in pre- end-stage renal disease ( ESRD) patients, and concluded that randomized controlled trials (RCTs) are necessary to evaluate the benefits and harms of correcting metabolic acidosis in pre- ESRD patients. We wanted to evaluate if the administration of alcaly (mainly sodium bicarbonate) is able to significantly modify renal death and to reduce mortality due to cardiovascular events. METHODS: This is a proposal for a multicenter, prospective, cohort, randomized and controlled study. We will randomize 600 patients with chronic kidney disease (CKD) stages 3b and 4; 300 of these patients will be included in the bicarbonate study group ( Bic), in which levels of bicarbonate should be kept >24 mEq/L; the other 300 patients will be included in the usual-treatment group (no- Bic). RESULTS: CONCLUSIONS:
|
Authors | Biagio Di Iorio, Filippo Aucella, Giuseppe Conte, Adamasco Cupisti, Domenico Santoro |
Journal | Journal of nephrology
(J Nephrol)
2012 May-Jun
Vol. 25
Issue 3
Pg. 437-40
ISSN: 1724-6059 [Electronic] Italy |
PMID | 21928233
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Acidosis
(blood, drug therapy, etiology, mortality)
- Cardiovascular Diseases
(etiology, mortality, prevention & control)
- Humans
- Italy
- Kidney Failure, Chronic
(blood, complications, mortality, therapy)
- Prospective Studies
- Renal Dialysis
- Renal Insufficiency, Chronic
(blood, complications, drug therapy, mortality)
- Research Design
- Sodium Bicarbonate
(blood, therapeutic use)
- Time Factors
- Treatment Outcome
|